Xenta Colloidal Gold Rapid Test Kits

Xenta Biomedical Science Co.,Ltd

China

Xenta Biomedical Science Co., Ltd, founded in December 2021 and headquartered in Guangzhou Development District, is a national high-tech enterprise focused on the R&D, registration, and commercialization of in vitro diagnostic (IVD) reagents and devices. With fully paid-up capital of RMB 10 million, the company is led by a team of returnee PhDs with strong international research and industry experience. It is dedicated to developing innovative POCT technology platforms under the philosophy of "Faster, Better, and More Accessible". The company drives innovation through R&D centers in Guangzhou, Xiamen, and overseas. Using its proprietary dry light-excited chemiluminescence POCT platform, it has developed leading product series and managed major national research projects. The company has published over 20 SCI papers, holds 70 patents, has obtained more than 60 EU CE certifications, and 12 FDA approvals in the United States. Currently, several product lines are actively striving for NMPA certification. Its pipeline covers key areas including cardiovascular, inflammation, oncology, hormone, and infectious diseases, demonstrating end-to-end capabilities from R&D to global commercialization. The core team comprises graduates from top universities such as Texas A&M University, Xiamen University, Sanford-Burnham Medical Research Institute, and Sun Yat-sen University, possessing multidisciplinary expertise in biomedicine, engineering, and law. The co-founders have extensive experience from leading IVD companies, having previously guided teams to achieve annual revenues exceeding several hundred million yuan and secure over 200 product certifications worldwide. Since its establishment, Xenta Biomedical Science Co., Ltd has raised tens of millions in funding and obtained ISO 13485 certification, supporting its global expansion.